A protein called Runx2 contributes to the abnormal activity of lung cells that drive pulmonary fibrosis, a new study…
Articles by Marisa Wexler, MS
Nerandomilast, an oral treatment being developed by Boehringer Ingelheim, bested a placebo at preserving lung function in adults with…
Mediar Therapeutics is planning to launch a Phase 2 clinical trial to test its experimental therapy MTX-463 in people…
CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in…
Reviva Pharmaceuticals has been awarded a U.S. patent covering the use of its experimental therapy brilaroxazine in treating…
In the U.K., patients with idiopathic pulmonary fibrosis (IPF) who live in economically deprived neighborhoods have worse survival outcomes…
Almee, a behavioral therapy app designed to help ease anxiety in people with pulmonary fibrosis (PF), has been granted…
A Phase 2a clinical trial has finished testing the experimental therapy ENV-101 (taladegib) in people with idiopathic pulmonary fibrosis…
Bersiporocin, an oral therapy for idiopathic pulmonary fibrosis (IPF) now being tested in a Phase 2 clinical trial, has…
LYT-100, PureTech Health’s oral treatment candidate for idiopathic pulmonary fibrosis (IPF), was well tolerated among healthy older adults…